EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Identification of AMPD2 allosteric inhibitors with novel mechanism of action by fragment merging approach

Kenji Yamanaka, Toru Uhara, Akihiro Nomura, Tatsuo Akaki, Tsuyoshi Adachi, Yuki Kitao, Yoshiji Hantani

SLAS Discovery · 2026-09 · 42 · 100313

DOI: 10.1016/j.slasd.2026.100313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLAS Discovery, 2026-09. Verfasst von Kenji Yamanaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka …. Hauptthemen laut MEDLINE: AMP Deaminase, Enzyme Inhibitors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenosine monophosphate deaminase 2 (AMPD2) catalyzes the conversion of adenosine monophosphate (AMP) to inosine monophosphate and is believed to play a significant role in nucleotide metabolism, energy homeostasis, and immune oncology. Three primary AMPD isozymes, designated as M (muscle), L (liver), and E (erythrocyte) forms, have been identified. However, due to the high similarity of the catalytic site's amino acid sequence and structural topologies, most reported orthosteric inhibitors exhibit minimal selectivity toward AMPD isozymes. There is therefore a significant need for selective AMPD2 inhibitors as tools for validating the biological roles of AMPD2. In this study, we hypothesized that allosteric AMPD2 inhibitors would show selectivity towards other AMPD isoforms and used an X-ray fragment screening approach to identify these inhibitors. Consequently, we identified compound 5, which showed the capacity to bind to a previously uncharacterized allosteric site. The pharmacophore search based on structural information around 5 and the following X-ray screening also identified 6 and 8, which bind to the same site as 5. The merging of the initial fragment hit 5 with the secondary fragment hit 6 yielded 7, which was further merged with 8, resulting in the successful generation of 9. Moreover, the optimization of 9 led to more potent selective inhibitors 10g and 10h. Our results suggest that the fragment merging method using X-ray screening and pharmacophore searching provides effective opportunities to improve the affinity of the fragment hits. In addition, we believe that these selective compounds could be used as tool compounds for studying the biological roles of AMPD2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AMP DeaminaseEnzyme InhibitorsAllosteric RegulationHumansAllosteric SitePharmacophoreCatalytic DomainCrystallography, X-RayProtein Binding

Stichwörter der Autor:innen

AMPD2Biophysical assayFragment mergingFragment screening

Substanzen

AMP DeaminaseEnzyme Inhibitors

Autor:innen und Institutionen

  • Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan. Electronic address: kenji.yamanaka@jt.com.
  • Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
  • Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
  • Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan. Electronic address: yoshiji.hantani@xforestx.com.

Zitieren

APA

Yamanaka, K., Uhara, T., Nomura, A., Akaki, T., Adachi, T., Kitao, Y., & Hantani, Y. (2026). Identification of AMPD2 allosteric inhibitors with novel mechanism of action by fragment merging approach. SLAS Discovery, 42, 100313. https://doi.org/10.1016/j.slasd.2026.100313

Vancouver

Yamanaka K, Uhara T, Nomura A, Akaki T, Adachi T, Kitao Y, et al. Identification of AMPD2 allosteric inhibitors with novel mechanism of action by fragment merging approach. SLAS Discovery. 2026;42:100313. doi:10.1016/j.slasd.2026.100313

BibTeX
@article{Yamanaka2026,
  author = {Yamanaka, Kenji and Uhara, Toru and Nomura, Akihiro and Akaki, Tatsuo and Adachi, Tsuyoshi and Kitao, Yuki and Hantani, Yoshiji},
  title = {Identification of AMPD2 allosteric inhibitors with novel mechanism of action by fragment merging approach},
  journal = {SLAS Discovery},
  year = {2026},
  volume = {42},
  pages = {100313},
  doi = {10.1016/j.slasd.2026.100313}
}
Kostenlos starten →